Sign In
Buy LGVN
$0.80
-0.0197 (-2.40%)
At Close: Jun 22, 2026
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
04:05pm, Monday, 04'th Nov 2024
Longveron will report third quarter 2024 financial results and provide a business update on Tuesday, November 12th after the U.S. financial markets close.
Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-B™ for mild Alzheimer's disease (AD) Lomecel-B™ capacity to inhibit MMP14 correlates wi
Oral presentation highlights findings that patients treated with Lomecel-B TM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none re
Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer's Disease Conf (CTAD24).
Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society Mtg.
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
09:05am, Monday, 07'th Oct 2024
Wa'el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
09:05am, Wednesday, 02'nd Oct 2024
Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.
Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa
09:05am, Thursday, 26'th Sep 2024
Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04:05pm, Monday, 26'th Aug 2024
MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agi
Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript
07:58pm, Wednesday, 14'th Aug 2024
Longeveron, Inc. (NASDAQ:LGVN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Lo
The Top 3 Small-Cap Stocks to Buy Now: Summer 2024
04:41pm, Thursday, 01'st Aug 2024
Small-cap stocks are back in favor. After languishing behind their larger brethren for years, small-cap stocks are roaring ahead as investors rotate into the sector once more.
Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates
09:16am, Monday, 29'th Jul 2024
Longeveron (NASDAQ: LGVN ) jumped after publishing a press release stating that Phase 2a results for its Alzheimer's treatment met primary endpoints. Lomecel-B is a treatment for mild cases of Alzheim
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer's Association International Conf
Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
04:05pm, Friday, 19'th Jul 2024
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular thera
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:45am, Thursday, 18'th Jul 2024
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular thera
